Human TRAILR1/TNFRSF10A Antibody | R&D Systems MAB347 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TRAILR1/TNFRSF10A Antibody

catalog :

MAB347

quantity :

100 ug (also 25 ug, 500 ug)

price :

359 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

69036

reactivity :

human

application :

immunohistochemistry, flow cytometry

citations: 22

Reference
Stöhr D, Schmid J, Beigl T, Mack A, Maichl D, Cao K, et al. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death Differ. 2020;: pubmed publisher
Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS ONE. 2018;13:e0198203 pubmed publisher
Jaworska D, Szliszka E. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. Int J Mol Sci. 2017;18: pubmed publisher
Kang Z, Goldstein S, Yu Y, Meltzer P, Loeb D, Cao L. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma. Br J Cancer. 2015;113:894-901 pubmed publisher
Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem. 2014;289:16576-87 pubmed publisher
Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
Suzuki Karasaki M, Ochiai T, Suzuki Karasaki Y. Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells. Int J Oncol. 2014;44:616-28 pubmed publisher
Stenqvist A, Nagaeva O, Baranov V, Mincheva Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J Immunol. 2013;191:5515-23 pubmed publisher
Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. PLoS ONE. 2013;8:e58855 pubmed publisher
Neumann S, Bidon T, Branschädel M, Krippner Heidenreich A, Scheurich P, Doszczak M. The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. PLoS ONE. 2012;7:e42526 pubmed publisher
Moniri M, Sun X, Rayat J, Dai D, Ao Z, He Z, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19:652-8 pubmed publisher
Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011;17:3181-92 pubmed publisher
Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J Cell Physiol. 2010;222:357-64 pubmed publisher
Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114:3854-63 pubmed publisher
Seal S, Hockenbery D, Spaulding E, Kiem H, Abbassi N, Deeg H. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol. 2008;36:1660-72 pubmed publisher
Shankar S, Chen Q, Ganapathy S, Singh K, Srivastava R. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther. 2008;7:2328-38 pubmed publisher
Toscano F, Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle J, et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene. 2008;27:4161-71 pubmed publisher
Weinmann L, Wischhusen J, Demma M, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008;15:718-29 pubmed publisher
Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008;104:595-605 pubmed
Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441-51 pubmed
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667-80 pubmed
Singh T, Shankar S, Srivastava R. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24:4609-23 pubmed

product information

brand :

R&D Systems

master code :

MAB347

SKU :

MAB347-100

product name :

Human TRAILR1/TNFRSF10A Antibody

description :

The Human TRAILR1/TNFRSF10A Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR1/TNFRSF10A. This antibody reacts with human. The Human TRAILR1/TNFRSF10A Antibody has been validated for the following applications: Flow Cytometry, Immunohistochemistry, CyTOF-ready.

target :

TRAILR1/TNFRSF10A

category :

Primary Antibodies

unit size :

100 ug (also 25 ug, 500 ug)

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

clonality :

Monoclonal

clone :

69036

conjugate :

Unconjugated

host :

Mouse

immunogen :

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A, Ala24-Asn239, Accession # AAC51226

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human

specificity :

Detects recombinant human TRAIL R1/TNFRSF10A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R3, rhTRAIL R4, or rhDcR3 is observed.

gene symbol :

TNFRSF10A

details of functionality :

ActivityAssaywCitation not found None None

catalog number base :

MAB347

accessionNumbers :

AAC51226

applications :

Flow Cytometry, Immunohistochemistry, CyTOF-ready

2020 USD :

339

2021 USD :

359 USD

alt names :

APO2, CD261, CD261 antigen, cytotoxic TRAIL receptor, Death receptor 4, DR4, DR4 TRAIL receptor 1, TNF-related apoptosis inducing ligand receptor 1, TNF-related apoptosis-inducing ligand receptor 1, TNFRSF10A, TRAIL R1, TRAIL-R1, TRAILR-1, TRAILR1MGC9365, tumor necrosis factor receptor superfamily member 10A, tumor necrosis factor receptor superfamily, member 10a

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.